[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1997

Cicatricial Pemphigoid Successfully Treated With Pulse Intravenous Cyclophosphamide

Author Affiliations

Department of Dermatology University of Texas Southwestern Medical Center 5323 Harry Hines Blvd Dallas, TX 75235-9069

Dallas

Arch Dermatol. 1997;133(2):245-247. doi:10.1001/archderm.1997.03890380119026
Abstract

Cicatricial pemphigoid (CP) is an uncommon autoimmune vesiculobullous disease that most commonly involves the mucous membranes of the mouth and eye. Treatment for CP varies, depending on location and severity; however, systemic therapy with immunosuppressive agents is usually indicated for disease that is rapidly progressing, recalcitrant to conservative treatment, or sight threatening. We report a case of ocular CP successfully treated with a combination of oral prednisone, low-dose oral cyclophosphamide, and high-dose pulse intravenous (IV) cyclophosphamide therapy.

Report of a Case.  A 66-year-old white woman was first seen in August 1992 with a 2-month history of a blistering dermatosis in her mouth. Initial physical examination findings revealed a tense blister on the right lower gingival mucosa. An oral mucosal biopsy sample showed epithelial subbasilar cleavage, consistent with CP. Topical treatment with 0.05% fluocinonide (Lidex gel, Syntex Laboratories Inc, Palo Alto, Calif) and 0.05% halobetasol propionate (Ultravate ointment, Westwood-Squibb Pharmaceuticals Inc, Buffalo, NY) was begun; however, over the next year

First Page Preview View Large
First page PDF preview
First page PDF preview
×